Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) – Wedbush issued their Q3 2017 earnings per share (EPS) estimates for Nightstar Therapeutics PLC Sponsored ADR in a research report issued to clients and investors on Monday. Wedbush analyst D. Nierengarten expects that the company will earn ($0.14) per share for the quarter. Wedbush has a “Outperform” rating and a $19.00 price target on the stock. Wedbush also issued estimates for Nightstar Therapeutics PLC Sponsored ADR’s Q4 2017 earnings at ($0.23) EPS, FY2017 earnings at ($0.63) EPS, FY2018 earnings at ($1.18) EPS, FY2019 earnings at ($1.39) EPS, FY2020 earnings at ($1.49) EPS and FY2021 earnings at ($1.08) EPS.

Other equities research analysts have also recently issued research reports about the stock. Leerink Swann assumed coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a research report on Monday. They issued an “outperform” rating and a $25.00 price objective for the company. Jefferies Group LLC assumed coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a research report on Monday. They issued a “buy” rating and a $25.00 price objective for the company. Finally, BMO Capital Markets assumed coverage on shares of Nightstar Therapeutics PLC Sponsored ADR in a research report on Monday. They issued an “outperform” rating and a $30.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/25/nightstar-therapeutics-plc-sponsored-adr-nite-expected-to-earn-q3-2017-earnings-of-0-14-per-share.html.

Nightstar Therapeutics PLC Sponsored ADR (NITE) opened at 18.77 on Wednesday. The company’s market capitalization is $527.46 million. Nightstar Therapeutics PLC Sponsored ADR has a 12-month low of $14.56 and a 12-month high of $24.93. The stock has a 50 day moving average of $18.94 and a 200 day moving average of $18.94.

An institutional investor recently bought a new position in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors acquired a new stake in Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned approximately 0.22% of Nightstar Therapeutics PLC Sponsored ADR at the end of the most recent quarter.

Nightstar Therapeutics PLC Sponsored ADR Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.